• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    da Silva, I. P.
    Ahmed, T.
    Reijers, I. L. M.
    Warner, A. B.
    Patrinely, J. R.
    Serra-Bellver, Patricio
    Allayous, C.
    Mangana, J.
    Zimmer, L.
    Trojaniello, C.
    Klein, O.
    Gerard, C. L.
    Michielin, O.
    Haydon, A.
    Ascierto, P. A.
    Carlino, M. S.
    Lebbe, C.
    Lorigan, Paul C
    Johnson, D. B.
    Sandhu, S.
    Lo, S. N.
    Menzies, A. M
    Long, G. V.
    Show allShow less
    Affiliation
    Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    None
    Citation
    da Silva IP, Ahmed T, Reijers ILM, Warner AB, Patrinely JR, Serra-Bellver P, et al. Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors’ reply. The Lancet Oncology. 2021 Aug;22(8):e343–4.
    Journal
    Lancet Oncology
    URI
    http://hdl.handle.net/10541/624517
    DOI
    10.1016/s1470-2045(21)00419-8
    PubMed ID
    34339647
    Additional Links
    https://dx.doi.org/10.1016/s1470-2045(21)00419-8
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/s1470-2045(21)00419-8
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma.
    • Authors: Li M
    • Issue date: 2021 Aug
    • Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    • Authors: Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV
    • Issue date: 2021 Jun
    • Nivolumab plus ipilimumab in melanoma brain metastases - Authors' reply.
    • Authors: Tawbi HA, Eroglu Z, Anders CK, Margolin KA
    • Issue date: 2022 Feb
    • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    • Authors: Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD
    • Issue date: 2018 Nov
    • Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    • Authors: Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kieker F, Dippel E, Rösch A, Simon JC, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D, Dermatologic Cooperative Oncology Group
    • Issue date: 2020 May 16
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.